Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase

Marc R. Reboll(Medizinische Hochschule Hannover), Stefanie Klede(Medizinische Hochschule Hannover), Manuel H. Taft(Medizinische Hochschule Hannover), Chen‐Leng Cai(Indiana University School of Medicine), Loren J. Field(Indiana University – Purdue University Indianapolis), Kory J. Lavine(Washington University in St. Louis), Andrew L. Koenig(Washington University in St. Louis), Jenni Fleischauer(Medizinische Hochschule Hannover), Johann Meyer(Medizinische Hochschule Hannover), Axel Schambach(Medizinische Hochschule Hannover), Hans W.M. Niessen(Amsterdam University Medical Centers), Maike Kosanke(Medizinische Hochschule Hannover), Joop van den Heuvel(Helmholtz Centre for Infection Research), Andreas Pich(Medizinische Hochschule Hannover), Johann Bauersachs(Medizinische Hochschule Hannover), Xuekun Wu(Medizinische Hochschule Hannover), Linqun Zheng(Medizinische Hochschule Hannover), Yong Wang(Medizinische Hochschule Hannover), Mortimer Korf‐Klingebiel(Medizinische Hochschule Hannover), Felix Polten(Medizinische Hochschule Hannover), Kai C. Wollert(Medizinische Hochschule Hannover)
Science
June 16, 2022
Cited by 114Open Access
Full Text

Abstract

Effective tissue repair after myocardial infarction entails a vigorous angiogenic response, guided by incompletely defined immune cell–endothelial cell interactions. We identify the monocyte- and macrophage-derived cytokine METRNL (meteorin-like) as a driver of postinfarction angiogenesis and high-affinity ligand for the stem cell factor receptor KIT (KIT receptor tyrosine kinase). METRNL mediated angiogenic effects in cultured human endothelial cells through KIT-dependent signaling pathways. In a mouse model of myocardial infarction, METRNL promoted infarct repair by selectively expanding the KIT-expressing endothelial cell population in the infarct border zone. Metrnl -deficient mice failed to mount this KIT-dependent angiogenic response and developed severe postinfarction heart failure. Our data establish METRNL as a KIT receptor ligand in the context of ischemic tissue repair.


Related Papers